Genor Biopharma Holdings Limited (HKG: 6998) has announced a definitive merger agreement with EOC Pharma Group (China) Co., Ltd. As part of the agreement, Genor Biopharma will acquire EOC Pharma through a share exchange, resulting in a reverse takeover. The company will change its name to “Edding Genor Group Holdings Limited” The transaction values Genor Biopharma at USD 197 million and EOC Pharma at USD 677 million. Upon completion, EOC Pharma’s controlling shareholder will hold a 77.43% stake in the merged entity.
EOC Pharma, a biopharmaceutical company focusing on anti-infective, cardiovascular, and respiratory treatments, has an established commercial platform and marketing network. In contrast, Genor Biopharma has not yet achieved commercialization but has a differentiated oral CDK4/6 inhibitor, lerociclib (GB491), nearing commercialization. The merger is expected to leverage complementary strengths and create synergies.
Genor Biopharma has entered into a CDK4/6i outsourcing management agreement with EOC Pharma Group, delegating EOC Pharma to handle all matters related to GB491 during the transition period, including new drug applications, manufacturing, supply chain management, and other related services.- Flcube.com
